Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $15.60.

Several brokerages recently commented on KLRS. TD Cowen began coverage on shares of Kalaris Therapeutics in a report on Monday, June 15th. They issued a “buy” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Tuesday, June 9th. Citigroup reiterated an “outperform” rating on shares of Kalaris Therapeutics in a report on Wednesday, May 13th. Wedbush began coverage on shares of Kalaris Therapeutics in a report on Thursday, May 14th. They issued an “outperform” rating and a $17.00 target price on the stock. Finally, Morgan Stanley began coverage on shares of Kalaris Therapeutics in a report on Thursday, April 16th. They issued an “overweight” rating and a $14.00 target price on the stock.

Insider Buying and Selling

In other news, Director Srinivas Akkaraju bought 244,300 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average price of $4.83 per share, for a total transaction of $1,179,969.00. Following the acquisition, the director directly owned 2,224,147 shares of the company’s stock, valued at $10,742,630.01. The trade was a 12.34% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 68.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of KLRS. Nano Cap New Millennium Growth Fund L P bought a new position in Kalaris Therapeutics in the 4th quarter worth $34,000. Barclays PLC bought a new position in shares of Kalaris Therapeutics during the 4th quarter worth about $51,000. Johnson Financial Group Inc. bought a new position in shares of Kalaris Therapeutics during the 3rd quarter worth about $58,000. XTX Topco Ltd bought a new position in shares of Kalaris Therapeutics during the 2nd quarter worth about $65,000. Finally, WealthTrust Asset Management LLC bought a new position in shares of Kalaris Therapeutics during the 1st quarter worth about $72,000. Institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Stock Performance

Kalaris Therapeutics stock opened at $4.72 on Tuesday. The company has a market capitalization of $112.29 million, a P/E ratio of -2.20 and a beta of 0.15. The firm’s fifty day simple moving average is $5.19 and its 200-day simple moving average is $7.36. Kalaris Therapeutics has a 1-year low of $2.14 and a 1-year high of $11.88.

Kalaris Therapeutics (NASDAQ:KLRS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.06. On average, equities research analysts predict that Kalaris Therapeutics will post -2.05 earnings per share for the current year.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.